Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study-Reference-Cited by-同舟云学术

Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study

Published:2023-06-09 Issue:7 Volume:128 Page:877-885
ISSN:1826-6983
Container-title:La radiologia medica
language:en
Short-container-title:Radiol med

Author:

Parisi Silvana,Ferini Gianluca,Lillo Sara^ORCID,Brogna Anna,Chillari Federico,Ferrantelli Giacomo,Settineri Nicola,Santacaterina Anna,Platania Angelo,Leotta Salvatore,Casablanca Giuseppe,Russo Alessandro,Pontoriero Antonio,Adamo Vincenzo,Minutoli Fabio,Bottari Antonio,Cacciola Alberto,Pergolizzi Stefano

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s11547-023-01659-w.pdf

Reference36 articles.

1. Cheema PK, Rothenstein J, Melosky B et al (2019) Perspectives on treatment advances for stage iii locally advanced unresectable non-small-cell lung cancer. Curr Oncol 26:37–42. https://doi.org/10.3747/co.26.4096

2. Bradley JD, Paulus R, Komaki R et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p. Lancet Oncol 16:187–199. https://doi.org/10.1016/S1470-2045(14)71207-0

3. Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after Chemoradiotherapy in stage III Non–small-cell lung cancer. N Engl J Med 377:1919–1929. https://doi.org/10.1056/nejmoa1709937

4. Faivre-Finn C, Vicente D, Kurata T et al (2021) Four-year survival with Durvalumab after Chemoradiotherapy in stage III NSCLC—an update from the Pacific trial. J Thorac Oncol 16:860–867. https://doi.org/10.1016/j.jtho.2020.12.015

5. Perez CA, Stanley K, Rubin P et al (1980) A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the radiation therapy oncology group. Cancer 45:2744–2753. https://doi.org/10.1002/1097-0142(19800601)45:11%3c2744::AID-CNCR2820451108%3e3.0.CO;2-U

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment for paraganglioma with stereotactic radiotherapy;World Journal of Clinical Cases;2024-06-06

2. Gene expression signature predicts radiation sensitivity in cell lines using the integral of dose–response curve;BMC Cancer;2024-01-02

3. A pH-Sensitive Nanoparticle as Reactive Oxygen Species Amplifier to Regulate Tumor Microenvironment and Potentiate Tumor Radiotherapy;International Journal of Nanomedicine;2024-01